Skip to content

Study · Non-randomized trial · n = 10 · 2018

4 results

Hypothalamic Response to Kisspeptin-54 and Pituitary Response to Gonadotropin-Releasing Hormone Are Preserved in Healthy Older Men.

Abbara A, Narayanaswamy S, Izzi-Engbeaya C, Comninos AN, Clarke SA, Malik Z, Papadopoulou D, Clobentz A, Sarang Z, Bassett P, Jayasena CN, Dhillo WS

Neuroendocrinology15 Mar 2018Cited by 11 (Europe PMC)

PMID29544222 (opens in a new tab)PMCIDPMC6008875 (opens in a new tab)DOI10.1159/000488452 (opens in a new tab)PepBankPUB-29544222
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

BackgroundMale testosterone levels decline by 1% per year from the age of 40 years. Whilst a primary testicular deficit occurs, hypothalamic or pituitary dysregulation may also coexist. This study aimed to compare the hypothalamic response to kisspeptin-54 and the pituitary response to gonadotropin-releasing hormone (GnRH) of older men with those of young men.MethodsFollowing 1 h of baseline sampling, healthy older men (n = 5, mean age 59.3 ± 2.9 years) received a 3-h intravenous infusion of either vehicle, kisspeptin-54 0.1, 0.3, or 1.0 nmol/kg/h or GnRH 0.1 nmol/kg/h, on five different study days. Serum gonadotropins and total testosterone were measured every 10 min and compared to those of young men (n = 5/group) (mean age 28.9 ± 2.0 years) with a similar body mass index (24 kg/m2) who underwent the same protocol.ResultsKisspeptin-54 and GnRH significantly stimulated serum gonadotropin release in older men compared to vehicle (p < 0.001 for all groups). Gonadotropin response to kisspeptin-54 was at least preserved in older men when compared to young men. At the highest dose of kisspeptin-54 (1.0 nmol/kg/h), a significantly greater luteinising hormone (LH) (p = 0.003) response was observed in older men. The follicle-stimulating hormone (FSH) response to GnRH was increased in older men (p = 0.002), but the LH response was similar (p = 0.38). Serum testosterone rises following all doses of kisspeptin-54 (p ≤ 0.009) were reduced in older men.ConclusionsOur data suggest that healthy older men without late-onset hypo-gonadism (LOH) have preserved hypothalamic response to kisspeptin-54 and pituitary response to GnRH, but impaired testicular response. Further work is required to investigate the use of kisspeptin-54 to identify hypothalamic deficits in men with LOH.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In healthy older men, the gonadotropin response to kisspeptin‑54 was at least preserved compared with young men.

    In plain wordsIn healthy older men, the hormone response to kisspeptin‑54 was at least as strong as in young men.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    No significant changeGonadotropin response in older versus young men
    Study

    n = 10

    Comparator
    Young men
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    0.1, 0.3, or 1.0 nmol/kg/h · intravenous · 3 hoursAs given in this study (human).

    Source sentences

    Summary
    Gonadotropin response to kisspeptin-54 was at least preserved in older men when compared to young men.
    2 context sentences
    Summary · context
    Following 1 h of baseline sampling, healthy older men (n = 5, mean age 59.3 ± 2.9 years) received a 3-h intravenous infusion of either vehicle, kisspeptin-54 0.1, 0.3, or 1.0 nmol/kg/h or GnRH 0.1 nmol/kg/h, on five different study days.
    Summary · context
    Serum gonadotropins and total testosterone were measured every 10 min and compared to those of young men (n = 5/group) (mean age 28.9 ± 2.0 years) with a similar body mass index (24 kg/m2) who underwent the same protocol.
  2. 02HumanNon-randomized trialEfficacy outcome

    At the highest dose of kisspeptin‑54, healthy older men had a significantly greater LH response than young men (p = 0.003).

    In plain wordsAt the highest kisspeptin‑54 dose, older men had a bigger luteinising hormone response than young men.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    IncreaseLH response at the highest kisspeptin-54 dose in older versus young men
    Study

    n = 10

    Comparator
    Young men
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    1.0 nmol/kg/h · intravenous · 3 hoursAs given in this study (human).

    Source sentences

    Summary
    At the highest dose of kisspeptin-54 (1.0 nmol/kg/h), a significantly greater luteinising hormone (LH) (p = 0.003) response was observed in older men.
    2 context sentences
    Summary · context
    Following 1 h of baseline sampling, healthy older men (n = 5, mean age 59.3 ± 2.9 years) received a 3-h intravenous infusion of either vehicle, kisspeptin-54 0.1, 0.3, or 1.0 nmol/kg/h or GnRH 0.1 nmol/kg/h, on five different study days.
    Summary · context
    Serum gonadotropins and total testosterone were measured every 10 min and compared to those of young men (n = 5/group) (mean age 28.9 ± 2.0 years) with a similar body mass index (24 kg/m2) who underwent the same protocol.
  3. 03HumanNon-randomized trialEfficacy outcome

    In healthy older men, the testosterone rises after all doses of kisspeptin‑54 were reduced compared with young men (p ≤ 0.009).

    In plain wordsIn healthy older men, testosterone rose less after kisspeptin‑54 than in young men.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreaseTestosterone rise after kisspeptin-54 in older versus young men
    Study

    n = 10

    Comparator
    Young men
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    0.1, 0.3, or 1.0 nmol/kg/h · intravenous · 3 hoursAs given in this study (human).

    Source sentences

    Summary
    Serum testosterone rises following all doses of kisspeptin-54 (p ≤ 0.009) were reduced in older men.
    2 context sentences
    Summary · context
    Following 1 h of baseline sampling, healthy older men (n = 5, mean age 59.3 ± 2.9 years) received a 3-h intravenous infusion of either vehicle, kisspeptin-54 0.1, 0.3, or 1.0 nmol/kg/h or GnRH 0.1 nmol/kg/h, on five different study days.
    Summary · context
    Serum gonadotropins and total testosterone were measured every 10 min and compared to those of young men (n = 5/group) (mean age 28.9 ± 2.0 years) with a similar body mass index (24 kg/m2) who underwent the same protocol.
  4. 04HumanNon-randomized trialEfficacy outcome

    In healthy older men, kisspeptin‑54 infusion significantly stimulated serum gonadotropin release compared with vehicle (p < 0.001).

    In plain wordsIn healthy older men, kisspeptin‑54 raised gonadotropin hormones in the blood more than vehicle.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    IncreaseGonadotropin release versus vehicle in older men
    Study

    n = 5

    Comparator
    Vehicle
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    0.1, 0.3, or 1.0 nmol/kg/h · intravenous · 3 hoursAs given in this study (human).

    Source sentences

    Summary
    Kisspeptin-54 and GnRH significantly stimulated serum gonadotropin release in older men compared to vehicle (p < 0.001 for all groups).
    2 context sentences
    Summary · context
    Following 1 h of baseline sampling, healthy older men (n = 5, mean age 59.3 ± 2.9 years) received a 3-h intravenous infusion of either vehicle, kisspeptin-54 0.1, 0.3, or 1.0 nmol/kg/h or GnRH 0.1 nmol/kg/h, on five different study days.
    Summary · context
    Serum gonadotropins and total testosterone were measured every 10 min and compared to those of young men (n = 5/group) (mean age 28.9 ± 2.0 years) with a similar body mass index (24 kg/m2) who underwent the same protocol.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.